Shilpa Medicare has launched the Indian branded generic of Dasatinib, an anticancer drug with a brand name ‘Dasashil’. Dasashil is first branded generic anticancer drug with all dosage strength 20/ 50/ 70/ 100 mg tablets which is used for the treatment of Chronic Myeloid Leukaemia (CML). Current, monthly therapy cost of innovator is approximately 1.65 lakh, with the launch of Dasashil monthly cost of treatment will be reduced drastically to Rs 6440 as monthly therapy cost.
Dasahil will revolutionise the treatment by ensuring to make therapy available for more Indian patients due to increased affordability. The products are being manufactured and supplied from the state-of-the-art US Food and Drug Administration (US FDA) approved manufacturing facility.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
